Perrigo Company plc (NYSE:PRGO) Given Average Recommendation of “Hold” by Analysts

Shares of Perrigo Company plc (NYSE:PRGO) have earned an average rating of “Hold” from the six analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has given a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $19.3333.

PRGO has been the topic of several research analyst reports. Weiss Ratings raised Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. Zacks Research raised shares of Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th.

Institutional Trading of Perrigo

A number of institutional investors have recently bought and sold shares of the company. Amundi increased its position in shares of Perrigo by 11.7% during the first quarter. Amundi now owns 5,292 shares of the company’s stock worth $148,000 after acquiring an additional 556 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Perrigo by 126.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock valued at $32,520,000 after acquiring an additional 647,982 shares during the last quarter. United Services Automobile Association purchased a new stake in Perrigo in the first quarter worth $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Perrigo by 6.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,112 shares of the company’s stock valued at $14,388,000 after acquiring an additional 32,151 shares during the period. Finally, Geneos Wealth Management Inc. lifted its stake in shares of Perrigo by 439.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after buying an additional 786 shares in the last quarter. Institutional investors own 95.91% of the company’s stock.

Perrigo Price Performance

Shares of PRGO traded down $0.01 during trading hours on Friday, hitting $11.01. 3,336,041 shares of the company were exchanged, compared to its average volume of 4,488,991. The company has a quick ratio of 1.59, a current ratio of 2.72 and a debt-to-equity ratio of 1.45. Perrigo has a fifty-two week low of $9.23 and a fifty-two week high of $28.43. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -0.84, a P/E/G ratio of 1.31 and a beta of 0.51. The firm’s fifty day moving average is $10.89 and its 200 day moving average is $12.12.

Perrigo (NYSE:PRGO) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.04. The business had revenue of $841.80 million during the quarter, compared to analysts’ expectations of $1.04 billion. Perrigo had a negative net margin of 43.50% and a positive return on equity of 9.96%. Perrigo’s revenue was down 7.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.60 earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, equities analysts anticipate that Perrigo will post 2.11 earnings per share for the current fiscal year.

Perrigo Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Friday, May 29th were paid a dividend of $0.29 per share. The ex-dividend date of this dividend was Friday, May 29th. This represents a $1.16 annualized dividend and a dividend yield of 10.5%. Perrigo’s dividend payout ratio (DPR) is presently -8.85%.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.